Question · asked by 1 review
CLOZAPINE + RISPERIDONE vs PLACEBO + CLOZAPINE: Global state: 2. no significant clinical improvement ‐ CGI, short term (up to 12 weeks)
- Population
- patients with schizophrenia
- Intervention
- CLOZAPINE + RISPERIDONE
- Comparison
- PLACEBO + CLOZAPINE
- Outcome
- Global state: 2. no significant clinical improvement ‐ CGI, short term (up to 12 weeks)
RISPERIDONE + CLOZAPINE showed no clear difference in global state: no significant clinical improvement ‐ CGI short term compared with PLACEBO + CLOZAPINE (low certainty).
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
RISPERIDONE + CLOZAPINE vs PLACEBO + CLOZAPINE Global state: no significant clinical improvement ‐ CGI short term · people with schizophrenia RISPERIDONE + CLOZAPINE showed no clear difference in global state: no significant clinical improvement ‐ CGI short term compared with PLACEBO + CLOZAPINE (low certainty). Risperidone versus placebo for schizophrenia (2016) · Cochrane Headline outcomes only | RR 1.12 [0.87, 1.44] | 1 study · 68 participants | Low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Risperidone versus placebo for schizophrenia 2016 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.